ConCallIQ
Go Pro
Home › Glenmark Pharmaceuticals › Revenue History

Glenmark Pharmaceuticals Revenue History — Quarter by Quarter

Glenmark Pharmaceuticals's revenue moved from ₹3,036 Cr in Q1 FY24 to ₹3,901 Cr in Q3 FY26, a 28.5% change over 11 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q3 FY26₹3,901 Cr+15.1%
Q2 FY26₹6,047 Cr+76%
Q1 FY26₹3,264 Cr+0.6%
Q4 FY25₹3,256 Cr+6.3%
Q3 FY25₹3,388 Cr+35.1%
Q2 FY25₹3,434 Cr+7.1%
Q1 FY25₹3,244 Cr+6.9%
Q4 FY24₹3,063 Cr+2.1%
Q3 FY24₹2,507 Cr-16%
Q2 FY24₹3,207 Cr+6.3%
Q1 FY24₹3,036 Cr+22.5%

What management said about revenue

G

Q3 FY26 · US respiratory approvals expected in Q4 FY26

Expecting FLOVENT 44 and other respiratory product approvals in Q4, which will drive US growth.

G

Q2 FY26 · India business Q3 run-rate of INR 1,150-1,200 crore

Management expects India formulation sales to return to INR 1,150-1,200 crore per quarter from Q3 FY26, with FY27 revenue exceeding INR 4,800 crore.

G

Q2 FY26 · FY27 revenue guidance of INR 17,000-18,000 crore

Management guided for FY27 consolidated revenue of INR 17,000-18,000 crore, implying ~15% growth over FY26 run-rate.

G

Q1 FY26 · India business to grow 10-15% CAGR over 3-5 years

Management expects India business to grow at 10-15% CAGR over the next three to five years, driven by branded products and new launches.

G

Q1 FY26 · Europe to return to double-digit growth from Q2 FY26

Management anticipates Europe region returning to double-digit growth from Q2 FY26 and expects double-digit growth for full year FY26.

G

Q1 FY26 · Emerging markets double-digit growth in FY26 on constant currency

Management expects emerging markets to record double-digit growth in FY26 on a constant currency basis.

G

Q4 FY25 · Revenue growth 10%-12% in FY26

Consolidated revenue from operations expected to grow 10%-12% year-over-year in FY2026.

G

Q4 FY25 · Generic Flovent 44 mcg approval by end of Q2 FY26

Expects approval for generic Flovent 44 mcg strength by end of Q2 FY2026, with launch thereafter.

G

Q3 FY25 · India business to achieve 9-10% growth for FY25

Management reiterated guidance of INR 1,100 crore per quarter average, implying 9-10% YoY growth for the full year.

G

Q3 FY25 · Fluticasone 44 MDI approval in H1 FY26

The company expects approval for Fluticasone 44 mcg MDI in the first half of FY26, with potential for earlier approval.

G

Q2 FY25 · First respiratory launch in 6-9 months

Glenmark expects to launch its first respiratory product in the US within 6-9 months, pending approval.

G

Q1 FY25 · Full-year EBITDA margin guidance of ~19%

Management guided to approximately 19% EBITDA margin for FY25, supported by India growth, RYALTRIS ramp-up, and lower R&D spend.